The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.
 
Brian I. Rini
Leadership - MashupMD; MJH Life Sciences
Stock and Other Ownership Interests - PTC Therapeutics
Consulting or Advisory Role - Alkermes; Aravive; Arrowhead Pharmaceuticals; Athenex; AVEO; Bristol-Myers Squibb; Corvus Pharmaceuticals; Debiopharm Group; Eisai; EUSA Pharma; Genentech; HiberCell; Merck; NiKang Therapeutics; Pfizer; Surface Oncology
Research Funding - ADC Therapeutics (Inst); Adela (Inst); Aravive (Inst); Arcus Biosciences (Inst); Arrowhead Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); Dracen (Inst); Dragonfly Therapeutics (Inst); Exelixis (Inst); Gilead Sciences (Inst); HiberCell (Inst); Incyte (Inst); Janssen (Inst); Merck (Inst); Pfizer (Inst); Pionyr (Inst); Point Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst); Stata (Inst); Surface Oncology (Inst); Vasgene Therapeutics (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Pfizer
 
Elizabeth R. Plimack
Consulting or Advisory Role - AstraZeneca; AVEO; Bristol-Myers Squibb/Medarex; Calithera Biosciences; EMD Serono; Exelixis; IMV; Janssen; Janssen; MEI Pharma; Merck; Pfizer; Regeneron; Seattle Genetics/Astellas; Signatera
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst)
 
Viktor Stus
Research Funding - Merck
 
Rustem Gafanov
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; MSD; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; MSD; Pfizer; Sanofi
Speakers' Bureau - Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; MSD; Pfizer; Sanofi
 
Tom Waddell
Honoraria - Bristol-Myers Squibb; EUSA Pharma; Ipsen; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai Europe; Ipsen; Merck Sharp & Dohme; Pfizer; Roche
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; EUSA Pharma; Ipsen
 
Dmitry Nosov
Consulting or Advisory Role - Johnson & Johnson/Janssen; Merck
 
Frederic Pouliot
Stock and Other Ownership Interests - Allogene Therapeutics
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Janssen; Novartis; Tersera; Tolmar
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Janssen; Merck; Tersera; Tolmar
Speakers' Bureau - Astellas Pharma; Bayer; Janssen
Research Funding - Astellas Pharma (Inst); Janssen (Inst); Merck (Inst); Tersera (Inst)
Patents, Royalties, Other Intellectual Property - Transcriptional system and uses therof for single cell detection
 
Boris Alekseev
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; MSD; Pfizer; Roche
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Janssen; Merck; MSD; Pfizer; Roche
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; MSD; Pfizer; Roche
Research Funding - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; MSD; Pfizer; Roche
Expert Testimony - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; MSD; Pfizer; Roche
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; MSD; Pfizer; Roche
 
Denis Soulieres
Honoraria - Adlai Nortye; AstraZeneca; Bristol-Myers Squibb; Eisai; Ipsen; Merck; Novartis; Pfizer
Consulting or Advisory Role - Adlai Nortye; Eisai; Ipsen; Merck; Pfizer
Research Funding - Adlai Nortye (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Bohuslav Melichar
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly O.; Merck Serono; MSD; Novartis; Pfizer; Roche; SERVIER
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly O.; Merck Serono; MSD; Novartis; Pfizer; Roche; SERVIER
Travel, Accommodations, Expenses - Merck Serono
 
Ihor O. Vynnychenko
No Relationships to Disclose
 
Sergio Jobim Azevedo
Consulting or Advisory Role - Grupo Oncoclinicas
 
Delphine Borchiellini
Consulting or Advisory Role - AAA/Endocyte/Novartis; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Merck; MSD Oncology; Pfizer
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Infinity Pharmaceuticals (Inst); Janssen (Inst); MSD (Inst); Roche (Inst); Taiho Oncology (Inst)
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Ipsen; Janssen; MSD Oncology; Pfizer
 
Raymond S. McDermott
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Clovis Oncology; Ipsen; Janssen; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi
Speakers' Bureau - MSD Oncology
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Ipsen; Janssen-Cilag; Pfizer; Roche
 
Jens Bedke
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Merck KGaA; MSD Oncology; Pfizer; Roche
Speakers' Bureau - Bristol-Myers Squibb; Ipsen; Merck KGaA; MSD Oncology; Pfizer
Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Ipsen (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst); SeaGen (Inst)
 
Satoshi Tamada
Speakers' Bureau - Merck; MSD; Pfizer; Takeda
 
Sterling Wu
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Joseph Burgents
Employment - Merck
 
L. Rhoda Molife
Employment - Merck
 
Thomas Powles
Honoraria - Astellas Pharma; AstraZeneca; BMS GmbH & Co. KG; Eisai; Exelixis; Exelixis; Gilead Sciences; Incyte; Ipsen; Johnson & Johnson/Janssen; MashupMD; MashupMD; Merck; Merck Serono; Merck Serono; Merck Sharp & Dohme LLC; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; MashupMD; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Johnson & Johnson; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; MSD; Pfizer; Roche